Jessica Botella-Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessica Botella-Garcia has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jordi Loscos-Arenas
Service of Ophthalmology, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain
2 shared publications - Kolbe Roche Fernández
Service of Ophthalmology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
2 shared publications - Pau Romera Romero
Germans Trias i Pujol Hospital, Catalan Institute of Health, Barcelona, Spain
2 shared publications - Rachid Bouchikh-El Jarroudi
Hospital Universitari Germans Trias i Pujol
2 shared publications - Adrian Sanchez-Fortun-Sanchez
Service of Ophthalmology, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain
1 shared publication Adrián Sánchez-Fortún
Hosp Germans Trias i Pujol, Dept Ophthalmol, Badalona 08916, Spain
1 shared publication
Latest Publications
- Open Access
- 28 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6085
Effectiveness and Safety of Mitomycin C in Deep Sclerectomy with the Esnoper Clip Implant: A Case Series Study
Objective: The objective was to provide evidence on the effectiveness (intraocular pressure, IOP) and safety of Deep Sclerectomy with the Esnoper Clip implant with and without the use of mitomycin C (MMC) in uncontrolled primary open-angle glaucoma. Methods: This was a multicentric, retrospective, consecutive case series study undertaken as a collaboration between University Hospital Trias i Pujol, Spain, and University Hospital Kralovske Vinohrady, Czech Republic. The IOP reduction was compared between patients who underwent Deep Sclerectomy with the Esnoper Clip implant, where the antifibrotic agent mitomycin C was used perioperatively (MMC group), and patients who underwent Deep Sclerectomy with Esnoper Clip implants where mitomycin C was not used either peri- or postoperatively (non-MMC group). At the end of the study (12 months after surgery), complete success probability (defined as an IOP p-value: 0.001; qualified success probability (95% confidence interval): 84.7% (76.6–93.7%) and 85.7% (75.8–97%), p-value: 0.188; and complications (total): 36 and 24, p-value: 0.286. Conclusions: In this case series study, the use of mitomycin C in Deep Sclerectomy with the Esnoper Clip implant for patients with uncontrolled primary open-angle glaucoma does not appear to improve IOP one year after surgery. No safety issues related to mitomycin C were observed. Further study is needed to confirm the effectiveness and to assess long-term safety.
- 28 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6085
Open AccessEffectiveness and Safety of Mitomycin C in Deep Sclerectomy with the Esnoper Clip Implant: A Case Series Study
Objective: The objective was to provide evidence on the effectiveness (intraocular pressure, IOP) and safety of Deep Sclerectomy with the Esnoper Clip implant with and without the use of mitomycin C (MMC) in uncontrolled primary open-angle glaucoma. Methods: This was a multicentric, retrospective, consecutive case series study undertaken as a collaboration between University Hospital Trias i Pujol, Spain, and University Hospital Kralovske Vinohrady, Czech Republic. The IOP reduction was compared between patients who underwent Deep Sclerectomy with the Esnoper Clip implant, where the antifibrotic agent mitomycin C was used perioperatively (MMC group), and patients who underwent Deep Sclerectomy with Esnoper Clip implants where mitomycin C was not used either peri- or postoperatively (non-MMC group). At the end of the study (12 months after surgery), complete success probability (defined as an IOP p-value: 0.001; qualified success probability (95% confidence interval): 84.7% (76.6–93.7%) and 85.7% (75.8–97%), p-value: 0.188; and complications (total): 36 and 24, p-value: 0.286. Conclusions: In this case series study, the use of mitomycin C in Deep Sclerectomy with the Esnoper Clip implant for patients with uncontrolled primary open-angle glaucoma does not appear to improve IOP one year after surgery. No safety issues related to mitomycin C were observed. Further study is needed to confirm the effectiveness and to assess long-term safety.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 1237-1246
Biomechanical Corneal Parameters in Eyes With Chronic Ocular Hypotony and in Non-Hypotonic Eyes. Self-Controlled Case Series Study
Introduction: There are no available data concerning corneal parameters in patients with chronic ocular hypotony. Our purpose is to provide evidence and clinical correlation on the biomechanical corneal changes in chronic hypotonic eyes. Patients and Methods: A single-center, transversal, self-controlled case series study was conducted involving patients with at least one chronic hypotonic eye (defined as an intraocular pressure ≤ 6.5 mmHg measured on three separate occasions for at least three months). The chronic hypotonic eye was the case and the contralateral eye the control (non-hypotonic eye). We collected data from baseline characteristic and intraocular pressure (mmHg). Biomechanical corneal parameters measured by Corvis ST: deformation amplitude ratio (mm), Ambrósio’s relational thickness (μm), stiffness parameter at first applanation (mmHg/mm), Integrated radius (mm− 1), stress-strain index, pachymetry (μm), and in addition macular folds were recorded as well. A descriptive and exploratory analysis was performed. Results: Between November 2021 and July 2023, a total of 16 consecutive patients (7 men, 9 women; age [median (range)]: 72 (62– 84)), diagnosed with chronic ocular hypotony in one eye were included: 16 chronic hypotonic eyes and 16 non-hypotonic eyes. Hypotonic versus non-hypotonic eyes [median (range)]: intraocular pressure: 4 (2– 6) mmHg, 16 (8– 38) mmHg; deformation amplitude ratio: 5.6 (4.3– 6.6) mm, 4.7 (3.9– 5.5) mm, p-value= 0.002; Ambrósio’s relational thickness: 482 (263– 932) μm, 530 (210– 818) μm, p-value: 0.845; stiffness parameter at first applanation: 61.5 (39– 100) mmHg/mm, 113 (68– 130) mmHg/mm, p-value: < 0.001; Integrated radius: 10.9 mm− 1 (6.3– 16.8), 7.9 mm− 1 (6.4– 10.5), p-value: < 0.001; stress-strain index: 0.7 (− 0.2– 4.9), 1.1 (− 2.7– 5.6), p-value: 0.034; pachymetry 509 (456– 617) μm, 512 (436– 775) μm, p-value: 0.637; and macular folds: 7/16, 0/16, p-value: < 0.001. Conclusions: Chronic hypotonic eyes (eyes with a low intraocular pressure) present biomechanical corneal changes with respect to non-hypotonic eyes, mainly in deformation amplitude ratio, stiffness parameter at first applanation, stress-strain index and Ambrósio’s relational thickness parameters. These biomechanical corneal changes could reflect softer, more elastic and deformable scleras, which at its turn can bear higher risk of hypotony maculopathy.
- 1 April 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 1237-1246
Open AccessBiomechanical Corneal Parameters in Eyes With Chronic Ocular Hypotony and in Non-Hypotonic Eyes. Self-Controlled Case Series Study
Introduction: There are no available data concerning corneal parameters in patients with chronic ocular hypotony. Our purpose is to provide evidence and clinical correlation on the biomechanical corneal changes in chronic hypotonic eyes. Patients and Methods: A single-center, transversal, self-controlled case series study was conducted involving patients with at least one chronic hypotonic eye (defined as an intraocular pressure ≤ 6.5 mmHg measured on three separate occasions for at least three months). The chronic hypotonic eye was the case and the contralateral eye the control (non-hypotonic eye). We collected data from baseline characteristic and intraocular pressure (mmHg). Biomechanical corneal parameters measured by Corvis ST: deformation amplitude ratio (mm), Ambrósio’s relational thickness (μm), stiffness parameter at first applanation (mmHg/mm), Integrated radius (mm− 1), stress-strain index, pachymetry (μm), and in addition macular folds were recorded as well. A descriptive and exploratory analysis was performed. Results: Between November 2021 and July 2023, a total of 16 consecutive patients (7 men, 9 women; age [median (range)]: 72 (62– 84)), diagnosed with chronic ocular hypotony in one eye were included: 16 chronic hypotonic eyes and 16 non-hypotonic eyes. Hypotonic versus non-hypotonic eyes [median (range)]: intraocular pressure: 4 (2– 6) mmHg, 16 (8– 38) mmHg; deformation amplitude ratio: 5.6 (4.3– 6.6) mm, 4.7 (3.9– 5.5) mm, p-value= 0.002; Ambrósio’s relational thickness: 482 (263– 932) μm, 530 (210– 818) μm, p-value: 0.845; stiffness parameter at first applanation: 61.5 (39– 100) mmHg/mm, 113 (68– 130) mmHg/mm, p-value: < 0.001; Integrated radius: 10.9 mm− 1 (6.3– 16.8), 7.9 mm− 1 (6.4– 10.5), p-value: < 0.001; stress-strain index: 0.7 (− 0.2– 4.9), 1.1 (− 2.7– 5.6), p-value: 0.034; pachymetry 509 (456– 617) μm, 512 (436– 775) μm, p-value: 0.637; and macular folds: 7/16, 0/16, p-value: < 0.001. Conclusions: Chronic hypotonic eyes (eyes with a low intraocular pressure) present biomechanical corneal changes with respect to non-hypotonic eyes, mainly in deformation amplitude ratio, stiffness parameter at first applanation, stress-strain index and Ambrósio’s relational thickness parameters. These biomechanical corneal changes could reflect softer, more elastic and deformable scleras, which at its turn can bear higher risk of hypotony maculopathy.
- 18 November 2023
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 16 (11) , 1806-1813
Efficacy and safety of deep sclerectomy with uveoscleral implant plus collagen matrix implant overcoming the superficial scleral flap in glaucoma surgery
AIM: To assess the efficacy and safety of non-penetrating deep sclerectomy (NPDS) with uveoscleral implant plus subconjunctival and intrascleral collagen matrix overcoming the superficial scleral flap lips (modified deep sclerectomy technique, DS) and minimal use of mitomycin C in glaucoma surgery. METHODS: A retrospective review of 47 consecutive glaucoma patients who underwent NPDS with DS between January 2017 and May 2018. Best-corrected visual acuity, intraocular pressure (IOP), post-operative need for glaucoma medications, visual field mean deviation (MD), re-interventions, needling revisions and laser goniopuncture were noted. Absolute success was defined as IOP <= 18 mm Hg without topical medication. Relative success was defined as the same criteria but with the addition of any antihypertensive medication. IOP over 18 mm Hg on two consecutive follow-up visits was considered as a failure. RESULTS: Fifty-two eyes of 47 patients were evaluated. Mean preoperative IOP was 25.37 +/- 6.47 mm Hg, and decreased to 15.04 +/- 4.73 at 12mo and 12.21 +/- 4.1 at 24mo (all P<0.0001). Requirement for topical medications dropped from a mean of 3.06 +/- 0.25 per patient to 0.51 +/- 0.99 and 1.11 +/- 1.23 respectively after 12 and 24mo (all P<0.0001). No medications were required in 45.5% of patients after 24mo. Relative and absolute success rate at 24mo were 85.5%+/- 5% and 48.5%+/- 7.4%, respectively. CONCLUSION: DS is a safe and effective non-penetrating glaucoma surgery variation. It aims to retain the patency of all pathways created for aqueous humor drainage: the intrascleral bleb, the supraciliary space and the open communication between intrascleral and subconjunctival compartments.
- 18 November 2023
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 16 (11) , 1806-1813
Efficacy and safety of deep sclerectomy with uveoscleral implant plus collagen matrix implant overcoming the superficial scleral flap in glaucoma surgery
AIM: To assess the efficacy and safety of non-penetrating deep sclerectomy (NPDS) with uveoscleral implant plus subconjunctival and intrascleral collagen matrix overcoming the superficial scleral flap lips (modified deep sclerectomy technique, DS) and minimal use of mitomycin C in glaucoma surgery. METHODS: A retrospective review of 47 consecutive glaucoma patients who underwent NPDS with DS between January 2017 and May 2018. Best-corrected visual acuity, intraocular pressure (IOP), post-operative need for glaucoma medications, visual field mean deviation (MD), re-interventions, needling revisions and laser goniopuncture were noted. Absolute success was defined as IOP <= 18 mm Hg without topical medication. Relative success was defined as the same criteria but with the addition of any antihypertensive medication. IOP over 18 mm Hg on two consecutive follow-up visits was considered as a failure. RESULTS: Fifty-two eyes of 47 patients were evaluated. Mean preoperative IOP was 25.37 +/- 6.47 mm Hg, and decreased to 15.04 +/- 4.73 at 12mo and 12.21 +/- 4.1 at 24mo (all P<0.0001). Requirement for topical medications dropped from a mean of 3.06 +/- 0.25 per patient to 0.51 +/- 0.99 and 1.11 +/- 1.23 respectively after 12 and 24mo (all P<0.0001). No medications were required in 45.5% of patients after 24mo. Relative and absolute success rate at 24mo were 85.5%+/- 5% and 48.5%+/- 7.4%, respectively. CONCLUSION: DS is a safe and effective non-penetrating glaucoma surgery variation. It aims to retain the patency of all pathways created for aqueous humor drainage: the intrascleral bleb, the supraciliary space and the open communication between intrascleral and subconjunctival compartments.